Holen Sie sich die Stockscreener-App
0.7369
7.09%
0.0488
Vorhandelsmarkt:
.73
-0.0069
-0.94%
Schlusskurs vom Vortag:
$0.6881
Offen:
$0.685
24-Stunden-Volumen:
358.20K
Relative Volume:
1.01
Marktkapitalisierung:
$3.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.07M
KGV:
-0.0527
EPS:
-13.99
Netto-Cashflow:
$-12.56M
1W Leistung:
+0.93%
1M Leistung:
+2.36%
6M Leistung:
-69.80%
1J Leistung:
-87.40%
1-Tages-Spanne:
$0.6753
$0.78
1-Wochen-Bereich:
$0.6201
$0.78
52-Wochen-Spanne:
$0.60
$5.71
Palisade Bio Inc Stock (PALI) Company Profile
Firmenname
Palisade Bio Inc
Sektor
Branche
Telefon
(858) 704-4900
Adresse
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Vergleichen Sie PALI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
0.7369 | 3.65M | 0 | -14.07M | -12.56M | -13.99 |
|
ONC
Beigene Ltd Adr
|
236.86 | 24.29B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.18 | 110.94B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2996 | 45.05M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
614.79 | 61.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.73 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Palisade Bio Inc Aktie (PALI) Neueste Nachrichten
Palisade Bio Q2 EPS Lifted by Brookline Capital Management - Defense World
Palisade Bio (NASDAQ:PALI) Earns “Buy” Rating from Brookline Capital Management - Defense World
Palisade Bio (PALI) Receives Buy Rating from Brookline Capital | - GuruFocus
Palisade Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
PALISADE BIO, INC. SEC 10-Q Report - TradingView
Palisade Bio reports positive data for UC drug trial - MSN
Palisade Bio (PALI) Projected to Post Quarterly Earnings on Monday - Defense World
Palisade Bio’s PALI-2108 shows promise in ulcerative colitis study - Investing.com
PALI Reports Positive Preclinical Outcomes for Ulcerative Colitis Treatment | PALI Stock News - GuruFocus
Palisade Bio’s PALI-2108 shows promise in ulcerative colitis study By Investing.com - Investing.com Canada
Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases - GlobeNewswire
New Ulcerative Colitis Drug PALI-2108 Outperforms Standard Treatments in Crucial Disease Models - Stock Titan
Analyzing Palisade Bio (NASDAQ:PALI) and Ginkgo Bioworks (NYSE:DNA) - Defense World
Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and - GlobeNewswire
Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit - Stock Titan
FY2025 EPS Estimates for Palisade Bio Increased by Analyst - American Banking and Market News
FY2025 EPS Forecast for Palisade Bio Raised by Analyst - Defense World
Analysts Issue Forecasts for Palisade Bio Q1 Earnings - Defense World
Palisade Bio reports safe PALI-2108 trials, eyes H1 2025 data - Investing.com Canada
Palisade Bio reports safe PALI-2108 trials, eyes H1 2025 data By Investing.com - Investing.com South Africa
Palisade Bio Completes Dosing In Phase 1A Portion Of Ongoing Phase 1A/B Study Of Pali-2108 - MarketScreener
Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108 - GlobeNewswire
Clinical Trial Success: Palisade Bio's UC Treatment Achieves Key Safety Milestone - Stock Titan
PALI stock plunges to 52-week low, touches $0.64 amid market challenges - Investing.com Australia
Palisade Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Palisade Bio Inc. (PALI) reports earnings - qz.com
PALI stock plunges to 52-week low, hitting $0.74 By Investing.com - Investing.com South Africa
PALI stock plunges to 52-week low, hitting $0.74 - Investing.com
Palisade Bio Inc expected to post a loss of $1.99 a shareEarnings Preview - TradingView
Palisade Bio (PALI) Expected to Announce Earnings on Tuesday - Defense World
Palisade Bio begins dosing subjects in last cohort of ulcerative colitis drug trial - Yahoo
Palisade Bio Begins Dosing Ulcerative Colitis Patients in PALI-2108 Trial -March 14, 2025 at 08:58 am EDT - Marketscreener.com
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108 - GlobeNewswire
Palisade Bio Reports Encouraging Preliminary Safety and Tolerability Data for PALI-2108 in Phase 1a/b Study for Ulcerative Colitis - Nasdaq
Palisade Bio's UC Treatment Advances: Zero Serious Events as Patient Trial Launches - StockTitan
Palisade Bio to present ulcerative colitis treatment data By Investing.com - Investing.com Australia
Palisade Bio Announces Two Abstracts Selected to be - GlobeNewswire
Palisade Bio to present ulcerative colitis treatment data - Investing.com
Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025 - GlobeNewswire
Palisade Bio (PALI) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Palisade Bio Participates in Virtual Investor 'What This Means” Segment - The Manila Times
Palisade Bio Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
Can Palisade Bio's Promising UC Drug Candidate Transform Treatment Options? - StockTitan
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Palisade Bio secures Canadian tax credit for drug study By Investing.com - Investing.com Nigeria
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) - The Manila Times
Palisade Bio secures Canadian tax credit for drug study - Investing.com India
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from - GlobeNewswire
Canadian Government Backs This Promising Ulcerative Colitis TreatmentWhat's Behind the $1.39M Investment? - StockTitan
Finanzdaten der Palisade Bio Inc-Aktie (PALI)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.33%
1.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):